Edward Tobinick

From Wikipedia, the free encyclopedia

Edward Lewis Tobinick is an American physician currently in full-time private practice in Los Angeles, California and he is an Assistant Clinical Professor of Medicine at the David Geffen School of Medicine at UCLA.[1] Tobinick holds a number of patents regarding the use of medical lasers for hair removal and etanercept, a drug that inhibits tumor necrosis factor-alpha to decrease its role in various inflammatory diseases.[2]

Tobinick has been issued patents for methods of perispinal administration, of certain recombinant DNA-derived (biologic) therapeutics including the TNF receptor fusion protein etanercept, for the treatment of certain neurologic disorders with widespread unmet medical need, including Alzheimer's disease; pain due to cancer metastasis to bone; severe, intractable, intervertebral disc-related pain and radiculopathy (including sciatica); and myasthenia gravis.[3] In addition, he originated the concept of the potential utility of etanercept, alone or in combination with oseltamivir for treatment of influenza (U.S. patent 6,419,934, filed September 5, 2000 [1]). For these novel treatment methods he has been issued multiple U.S. patents, including 6,015,557 (Tumor necrosis factor antagonists for the treatment of neurological disorders) [2]; 6,177,077 [3]; 6,419,934 [4]; and 6,982,089 [5]. In general, his concepts represent emerging therapeutic strategies which, although supported by small pilot studies, have not yet been confirmed by randomized clinical trials.[4]

Tobinick earned his M.D. from the UC San Diego School of Medicine in 1977.

[edit] Publications

  • Tobinick E, Gross H, Weinberger A, Cohen H. (2006). "TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study". Medscape General Medicine 8 (2): 25f. PMID 16926764. 
  • Tobinick E. (2006). "The Cerebrospinal Venous System: Anatomy, Physiology, and Clinical Implications". Medscape General Medicine 8 (1): 53f. PMID 16915183. 
  • Tobinick E, Davoodifar S. (2004). "Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients". Curr Med Res Opin 20 (7): 1075-85. PMID 15265252. 
  • Tobinick E, Britschgi-Davoodifar S. (2003). "Perispinal TNF-alpha inhibition for discogenic pain.". Clinical Therapeutics 25 (4): 1211-18. PMID 12809967. 
  • Tobinick E. (2003). "Targeted etanercept for discogenic neck pain: uncontrolled, open-label results in two adults.". Swiss Med Wkly 133 (11-12): 170-177. PMID 12715286. 
  • Tobinick E. (2003 (August)). "Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports.". Clinical Therapeutics 25 (8): 2279-88. PMID 14512134. 
  • Tobinick E. (2004). "TNF-alpha inhibition for potential therapeutic modulation of SARS coronavirus infection.". Curr Med Res Opin 20 (1): 39-40. PMID 14741070. 
  • Tobinick, Edward; Richard Usatine, Ronald Moy, Daniel Siegel (1998). Skin Surgery: A Practical Guide. St. Louis: Mosby. ISBN 0-8151-7362-8. 

[edit] References

  1. ^ UCLA Departments of Medicine and Family Medicine Clinical Faculty (Private Practice) Geographical Referral Roster
  2. ^ United States Patent and Trademark Office
  3. ^ United States Patent 6,423,321
  4. ^ Tobinick's private practice
  • Rosenberg P. (2006). "Editorial: Cytokine inhibition for treatment of Alzheimer's Disease". MedGenMed Neurology & Neurosurgery 8 (2): 1.  link
Retrieved from "http://en.wikipedia.org../../../e/d/w/Edward_Tobinick_6ec0.html"